KRAS and cancer: Given that cancer types with prevalent KRAS mutations exhibited a diverse microbial composition, and that intratumoral microbiota could contribute to resistance against chemotherapy and immunotherapy,[94] it is essential for future studies to explore changes in microbial composition associated with KRAS inhibitor treatment, and to identify specific intratumoral microbial species linked to treatment response or resistance.